Immune Modulators Have Mixed Results on COVID Pneumonia

In December of 2020, URMC researchers joined the large, national ACTIV-1 clinical trial testing whether immune modulator drugs can speed recovery for patients hospitalized with COVID. Though results are mixed, the trial provides many insights for future trials and pandemics. 

Protecting the Vulnerable, Informing the Future

In the early days of the COVID pandemic, members of the UR CTSI partnered with the URMC Intellectual and Developmental Disabilities Research Center and the Mary Cariola Center to study how COVID spread, so they could protect kids with intellectual and developmental disabilities.

UR CTSI Supports Program Using Improv to Address Vaccine Hesitancy

An Arts and Medicine article published in JAMA today describes a UR CTSI-supported program that turned to improv theater for help addressing vaccine hesitancy.

National Study: Early Treatment with COVID Convalescent Plasma Prevents Hospitalization

The UR CTSI was part of a national study published in the New England Journal of Medicine showing that plasma from patients who have recovered from COVID is a safe and effective early outpatient treatment for others with the disease.

UR CTSI-Supported Study: Immunity from Colds May Lead to Worse COVID Infection

Counterintuitive results from a new UR CTSI-supported study suggest that prior immunity to one of the seasonal cold coronaviruses may have put people at risk of more severe COVID illness and death.